Phase 1/2Status unknown

A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer

Sponsor
Panacela Labs LLC (Industry)
Enrollment
24 planned
Conditions
Prostate Cancer
Interventions
Mobilan (M-VM3); Placebo
Ages
adults, older adults
Registry
NCT02844699

Full record on ClinicalTrials.gov

From the registry

A Phase Ib2, multicenter, randomized, double-blind, placebo-controlled safety and efficacy study evaluating different regimens of the immunotherapeutic drug, Mobilan (M-VM3), in patients with prostate cancer.

Primary outcomes

  • Frequency and intensity of adverse events (according to CTCAE v 4.03 classification)
  • Counting of CD4+ and CD8+ cells in prostate biopsy and surgery samples

History

  1. Primary completion

  2. Last registry update

  3. Registered

  4. Started